



Chairman's Address to Shareholders 2017 Annual General Meeting 31 May 2018

Good afternoon ladies and gentleman. My name is Robert Proulx, Executive Chairman of Imagion Biosystems Limited, and I am delighted to welcome you to Imagion's inaugural Annual General Meeting.

Before we proceed to the formal business of the meeting, I would like to take the opportunity to address shareholders here today.

We all know that far too many people's lives are adversely affected by cancer and so our mission is clear - we have to develop a new, more sensitive way to detect and diagnose cancer.

MagSense™ technology is a whole new way to detect tumors providing functional imaging without the use of ionizing radiation. It will be safer for patients, less expensive than invasive biopsy procedures, and can be used to detect many types of cancer. And so the business opportunity is immense.

In my experience it is easy for companies to get distracted when the opportunity is large, but I'd like to reassure our shareholders that our business plan has been narrowly focused on the shortest path to commercial product introduction. We believe getting to our first test in humans will be a significant de-risking event that the markets will recognize.

I'm pleased to report that our plan to get to human testing remains on track and we have enough cash to get through the remaining major product development steps before that first-in-human testing begins.

I would like to thank our Board of Directors for their efforts and willingness to dedicate their time, and to our employees and collaborators for their diligent work towards improving the way cancer will be diagnosed. Finally, I would like to express my sincere thanks to our shareholders for their belief in, and support of, our mission.

-ENDS



About Imagion Biosystems

Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSense™ technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630